Speed is Life but a Sledgehammer Helps Too: Combination Antibiotic Therapy For Septic Shock
|
|
- Donald Hudson
- 5 years ago
- Views:
Transcription
1 Speed is Life but a Sledgehammer Helps Too: Combination Antibiotic Therapy For Septic Shock Anand Kumar MD, FRCPC, FCCP, FCCM Associate Professor of Medicine University of Manitoba Health Sciences Centre St. Boniface Hospital Winnipeg, Manitoba For available slides: /kumar.html akumar61@yahoo.com ` 1
2 Relationship of SIRS, Sepsis and Infection Sepsis Burns Severe sepsis Pancreatitis Infection Septic shock SIRS Trauma Post-pump syndrome 2
3 Sepsis and Septic Shock: An Intensivist s Immunologic View Antimicrobials Infection CARS SIRS Organ Injury Antiinflammatory (endogenous) Time RECOVERY van der Poll T, van Deventer SJH. Infect Dis Clin N Am akumar61@yahoo.com 3
4 Sepsis and Septic Shock: An ID-Microbiologic View Cellular dysfunction/tissue injury Inflammatory response Toxic burden Microbial load TIME 4
5 Carl J Wiggers ( ) Shock is a syndrome resulting from depression of many functions, but in which reduction of the effective circulating volume and blood pressure are of basic importance, and in which impairment of circulation steadily progresses until it eventuates in a state of irreversible circulatory failure. akumar61@yahoo.com
6 An Injury Paradigm of Septic Shock: The Golden Hours DEATH Cellular dysfunction/tissue injury Inflammatory response Toxic burden Shock Threshold Microbial load TIME 6
7 Speed is Life The speed of clearance of the microbial pathogen is the critical determinant of outcome in septic shock 7
8 An Injury Paradigm of Sepsis and Antimicrobial therapy Septic Shock Cellular dysfunction/tissue injury Inflammatory response Shock Threshold Toxic burden Microbial load TIME 8
9 Frapper fort et frapper vite Hit hard and fast -Paul Erlich, address to the 17 th International Congress of Medicine,
10 An Injury Paradigm of Sepsis and Septic Shock earlier antimicrobial therapy Cellular dysfunction/tissue injury Shock Threshold Microbial load Inflammatory response Toxic burden TIME 10
11 Cumulative Initiation of Effective Antimicrobial Therapy and Survival in Septic Shock fraction of total patients 1.0 survival fraction cumulative antibiotic initiation Kumar et al. CCM. 2006:34: time from hypotension onset (hrs) 11
12 more intense antimicrobial therapy An Injury Paradigm of Sepsis and Septic Shock Cellular dysfunction/tissue injury Inflammatory response Shock Threshold Toxic burden Microbial load TIME 12
13 Synergy ie 2 drugs Static vs cidal PK/PD: -time above MIC -AUIC akumar61@yahoo.com 13
14 Monotherapy vs Combination Therapy: Gram Negative Bacteremia Safdar N, Handelsman J, Maki DG, Lancet ID
15 Potential Reasons for Combination Therapy Superiority Increased breadth of activity Decreased risk of superinfection Favorable immunomodulatory effects of seconary antimicrobials Antimicrobial synergism 16
16 Cefotaxime and Gentamicin in Rat E. coli Bacteremia 1 0 antibiotic no Cf -1 Ge Ge Cf Cf Ge + Ge Cf Kumar et al, ICAAC Time from Antibiotic Administration (hr)
17 Combination Antimicrobial Therapy in ICU- Requiring CAP: Effect of Combination Therapy in Shock vs Non-shock Non-shock Shock Rodriguez A et al. CCM 2007;35: akumar61@yahoo.com
18 Monotherapy Mortality (%) scoulier et al 1982 kamad et al 1985 vasquez et al 2005 dwyer et al 2006 baddour et al 2004 rodriquez et al 2007 chow et al 1991 kim et al 2003 chokshi et al 2007 martinez et al 2003 damas et al 2006 korvick et al 1992 cometta et al 1994 kreger et al 1980 mccue et al 1985 bouza et al 1987 carbon et al 1987 harbath et al 2005 mccue et al 1987 siegman-igra et al 1998 gullberg et al 1989 leibovici et al 1997 heyland et al (mod) 2008 waterer et al 2001 dupont et al patterson et al 2003 kim et al 2002 fernandez-guerrero et al 1991 kuikka et al 1998 piccart et al 1984 bodey et al 1985 gamacho-montero et al 2007 mendelson et al 1994 vasquez et al 2005 chamot et al 2003 kljucar et al 1990 hilf et al 1989 harbarth et al 2005 aspa et al 2006 katersky et al 1973 montgomerie et al 1980 graninger et al 1992 fainstein et al 1983 maki et al 1988 dwyer et al 2005 gamacho-montero et al 2007 heyland et al (mod) 2008 chow et al 1991 korvick et al 1992 bodey et al 1989 baddour et al (rev) 2004 rodriquez et al 2007 feldman et al 1990 bodey et al 1985 chamot et al 2003 hilf et al 1989 tapper et al 1974 hammond et al 1990 combined (random) odds ratio (95% confidence interval) Meta-analysis of studies of combination vs monotherapy of life-threatening infections associated with sepsis and septic shock Kumar et al, Crit Care Med 2010;38:
19 Vazquez b Chamot a,c Kljucar D'Antonio Hilf a Watanakunkorn Klatersky Montgomerie Graninger Baddour b,c Ko Aspa Fainstein Maki Dwyer b Mendelson Garnacho-Montero b Chow b Heyland b,c Korvick b Bodey2 Rodriguez b Feldman Bodey1 b Chamot b,c Hilf b Tapper Hammond combined Monotherapy mortality >25% Monotherapy mortality 15-25% Odds ratio meta-analysis plot [random effects] Carbon McCue Kuikka Harbarth b,c Gullberg Siegman-Igra Leibovici Heyland a,c Waterer Dupont Patterson Kim Harbarth a,c Fernandez-Guerrero Kuikka Piccart Bodey1 a Garnacho-Montero a combined Sculier Karnad Vazquez a Dwyer a Baddour a,c Rodriguez a Chowa Kim Chokshi Martinez Damas Korvick a Cometta Kreger McCue Bouza combined Monotherapy mortality <15% odds ratio (95% confidence interval) Favors combination Favors monotherapy Kumar et al, Crit Care Med 2010;38:
20 Metaregression: All studies Odds Ratio of Death (Combination Therapy) OR ( ) per 10% mortality increment, p< Monotherapy Mortality Risk (%) Kumar et al, Crit Care Med 2010;38:
21 Metaregression: RCTs OR ( ) per 10% mortality increment, p=.0159 Odds Ratio of Death (Combination Therapy) Monotherapy Mortality Risk (%) Kumar et al, Crit Care Med 2010;38:
22 Meta-analysis (shock/critically ill stratified): Combination vs Monotherapy Group Odds Ratio I 2 (%) P-value non-shock 1.11 ( ) shock 0.54 ( ) non-critically ill 1.10 ( ) critically ill 0.33 ( ) non-shock/non-critically ill 1.10 ( ) shock/critically ill 0.49 ( ) 0 <.0001 overall 0.76 ( ) Combo Therapy Favored Monotherapy Favored Odds Ratio of Death Kumar et al, Crit Care Med ;38:
23 % Surviving MT vs CT: 28 day survival Combination Therapy (CT) Monotherapy (MT) Kumar et al, Crit Care Med 2010;38: Log-rank p-value: day CT MT Number at risk 24
24 Liberation from Pressors: Combination vs Mono-Therapy 100 Pressor dependence (%) log rank p-value = 0.03 Monotherapy Combined Therapy 0 # at risk Monotherapy Combined Therapy Time (days)
25 Combination vs Monotherapy: β -lactams Primary Antibiotic penicillins penicillin/ampicillin anti-staph penicillin β -lactam/inhibitor cephalosporins 1st gen ceph 2nd gen ceph non-ps 3rd gen ceph anti-ps 3rd/4th gen ceph carbapenem vancomycin fluoroquinolone macrolide/clindamycin n p value Kumar et al, Crit Care Med 2010;38: Hazard Ratio 26
26 Combination vs Monotherapy: Secondary Antibiotic β -lactams (n=930) AG FQ ML/CL other Vancomycin (n=82) AG FQ ML/CL other Fluoroquinolones (n=50) AG ML/CL All primary drugs (n=1223) AG FQ ML/CL n p value Kumar et al, Crit Care Med 2010;38: Hazard Ratio 27
27 Combination vs Monotherapy: all gram + GAS non-gas strep viridans strep S. pneumoniae S. aureus Enterococcus sp Organisms n p value E. coli Klebsiella sp Enterobacter sp other enterobacteriaciae all enterobacteriaciae Ps. aeruginosa Hemophilus sp other non-enterobacteriaciae all non-enterobacteriaciae all gram Kumar et al, Crit Care Med Hazard Ratio 2010;38:
28 Eventually, Billy came to dread his father s lectures over all other forms of punishment. 30
Empirical Antibiotic Therapy Combo vs Mono : Best
Empirical Antibiotic Therapy Combo vs Mono : Best Anand Kumar MD, FRCPC, FCCP, FCCM Professor of Medicine University of Manitoba Health Sciences Centre St. Boniface Hospital Winnipeg, Manitoba For available
More informationThe Sepsis Timebomb. James Wigfull Critical Care and Anaesthesia Sheffield Teaching Hospitals
The Sepsis Timebomb James Wigfull Critical Care and Anaesthesia Sheffield Teaching Hospitals Relationship of SIRS, Sepsis and Infection BACTEREMIA PANCREATITIS INFECTION FUNGEMIA PARASITEMIA VIREMIA SEPSIS
More informationTiming of Vasopressors in Septic Shock: How Soon is Too Soon?
Timing of Vasopressors in Septic Shock: How Soon is Too Soon? Anand Kumar, MD Sections of Critical Care Medicine and Infectious Diseases Professor of Medicine, Medical Microbiology and Pharmacology University
More informationAn alternate pathophysiologic paradigm of sepsis and septic shock Implications for optimizing antimicrobial therapy
Review Virulence 5:1, 80 97; January 1, 2014; 2014 Landes Bioscience An alternate pathophysiologic paradigm of sepsis and septic shock Implications for optimizing antimicrobial therapy Anand Kumar Section
More informationP. aeruginosa: Present therapeutic options in Intensive Care. Y. Van Laethem (CHU St-Pierre & Université libre de Bruxelles, Brussels, Belgium)
P. aeruginosa: Present therapeutic options in Intensive Care Y. Van Laethem (CHU St-Pierre & Université libre de Bruxelles, Brussels, Belgium) Activity vs Pseudomonas aeruginosa Pseudomonas aeruginosa
More informationMDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES
MDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES 1 Marin H. Kollef, MD Professor of Medicine Virginia E. and Sam J. Golman Chair in Respiratory Intensive Care Medicine Washington University School of
More informationGuess or get it right?
Guess or get it right? Antimicrobial prescribing in the 21 st century Robert Masterton Traditional Treatment Paradigm Conservative start with workhorse antibiotics Reserve more potent drugs for non-responders
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationICU Case Presentation: Double antimicrobial coverage for gram negative infections. Christine Rizkalla, RPh, BScPhm Pharmacy Resident May 16, 2007
ICU Case Presentation: Double antimicrobial coverage for gram negative infections Christine Rizkalla, RPh, BScPhm Pharmacy Resident May 16, 2007 Objectives Understand the theoretical advantages and disadvantages
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationCommunity Acquired Pneumonia. Background & Rationale to North American Guidelines. Lionel Mandell MD FRCPC Brussels Belgium
Community Acquired Pneumonia Background & Rationale to North American Guidelines Lionel Mandell MD FRCPC Brussels Belgium Consider Impact of the disease Issues to reflect upon Impact of the Disease 3-4
More informationSEPSIS AND SEPTICEMIA St. Charles Bend / Dec. 18, 2015
SEPSIS AND SEPTICEMIA St. Charles Bend / Dec. 18, 2015 DEFINITIONS SYSTEMIC INFLAMMATORY RESPONSE SYNDROME SEPSIS SEVERE SEPSIS SEPTIC SHOCK MULTIPLE ORGAN FAILURE BACTEREMIA SEPTICEMIA THOMAS C CESARIO
More informationSepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment
Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment What is sepsis? Life-threatening organ dysfunction caused by a dysregulated host response to infection A 1991 consensus
More informationAndrea Blotsky MDCM FRCPC General Internal Medicine, McGill University Thursday, October 15, 2015
The TIMES Project: (Time to Initiation of Antibiotic Therapy in Medical Patients Presenting to the Emergency Department with Sepsis) - Preliminary Findings Andrea Blotsky MDCM FRCPC General Internal Medicine,
More informationAminoglycosides as an antibiotic class maintain
SURGICAL INFECTIONS Volume 17, Number 3, 2016 ª Mary Ann Liebert, Inc. DOI: 10.1089/sur.2015.276 An Argument for the Use of Aminoglycosides in the Empiric Treatment of Ventilator-Associated Pneumonia Addison
More informationIs the package insert correct? PK considerations
Is the package insert correct? PK considerations Jason A Roberts B Pharm (Hons), PhD, FSHP Professor of Medicine and Pharmacy The University of Queensland, Australia Royal Brisbane and Women s Hospital,
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 15: , 2018
2418 Comparison of mono- and combination antibiotic therapy for the treatment of Pseudomonas aeruginosa bacteraemia: A cumulative meta analysis of cohort studies SU YU TANG 1*, SHUN WEN ZHANG 2*, JIANG
More informationLessons from recent studies. João Gonçalves Pereira UCIP DALI
Lessons from recent studies João Gonçalves Pereira UCIP DALI 1 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Cmax/MIC>10 Metronidazol Area under the concentration curve Azithromycin
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationSepsis is an important issue. Clinician s decision-making capability. Guideline recommendations
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012 Clinicians decision-making capability Guideline recommendations Sepsis is an important issue 8.7%
More informationTreatment Strategies for Infections due to MDR-GNR
Treatment Strategies for Infections due to MDR-GNR Michael Satlin, MD Instructor in Medicine Division of Infectious Diseases Weill Cornell Medical College, New York, NY October 16, 2012 1 2 Faculty Disclosure
More informationCURRENT GUIDELINES FOR SEPSIS MANAGEMENT
HELLENIC SEPSIS STUDY GROUP www.sepsis.gr CURRENT GUIDELINES FOR SEPSIS MANAGEMENT Evangelos J. Giamarellos-Bourboulis, MD, PhD Associate Professor of Medicine 4 th Department of Internal Medicine, National
More informationLa batteriocidia sierica: passato e presente
Genova, 23 settembre 2016 La batteriocidia sierica: passato e presente Dott.ssa Maddalena Giannella Clinica di Malattie Infettive AOU Policlinico Sant Orsola Malpighi Case 1 Case 2 Summary: Cured of cancer
More informationOptimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches
Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator
More informationEducational Workshop
Educational Workshop EW02: Management of severe sepsis and septic shock anno 2015 Arranged with ESGBIS & International Sepsis Forum (ISF) Convenors: W. Joost Wiersinga, Amsterdam, NL Tom van der Poll,
More informationCommunity Acquired & Nosocomial Pneumonias
Community Acquired & Nosocomial Pneumonias IDSA/ATS 2007 & 2016 Guidelines José Luis González, MD Clinical Assistant Professor of Medicine Outline Intro - Definitions & Diagnosing CAP treatment VAP & HAP
More informationSeptic Shock. Rontgene M. Solante, MD, FPCP,FPSMID
Septic Shock Rontgene M. Solante, MD, FPCP,FPSMID Learning Objectives Identify situations wherein high or low BP are hemodynamically significant Recognize complications arising from BP emergencies Manage
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationSep Oct Nov Dec Total
LB PAGE 2 LB PAGE 3 Sep Oct Nov Dec 2007 2007 2007 2007 Total Repeat Information Total Repeats 35 15 17 9 76 Repeat Rate 6.01% 0.17% 1.12% 0.39% 2.07% Repeat Chemistry 25 0 2 0 27 Repeat Extraction 1 0
More informationContinuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients
Continuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients Jan O Friedrich, MD DPhil Associate Professor of Medicine, University of Toronto Medical Director, MSICU St. Michael s Hospital,
More informationInfections In Cirrhotic patients. Dr Abid Suddle Institute of Liver Studies King s College Hospital
Infections In Cirrhotic patients Dr Abid Suddle Institute of Liver Studies King s College Hospital Infection in cirrhotic patients Leading cause morbidity/mortality Common: 30-40% of hospitalised cirrhotic
More informationSepsi: nuove definizioni, approccio diagnostico e terapia
GIORNATA MONDIALE DELLA SEPSI DIAGNOSI E GESTIONE CLINICA DELLA SEPSI Giovedì, 13 settembre 2018 Sepsi: nuove definizioni, approccio diagnostico e terapia Nicola Petrosillo Società Italiana Terapia Antiinfettiva
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationChoc septique. Frédéric Pène
Choc septique Frédéric Pène Réanimation Médicale, Hôpital Cochin, AP-HP Université Paris Descartes Institut Cochin, Inserm U1016, CNRS UMR-8104, Département 3i No conflict of interest A 54 y.o. male patient
More informationInitial Resuscitation of Sepsis & Septic Shock
Initial Resuscitation of Sepsis & Septic Shock Dr. Fatema Ahmed MD (Critical Care Medicine) FCPS (Medicine) Associate professor Dept. of Critical Care Medicine BIRDEM General Hospital Is Sepsis a known
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationPREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS
PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationby author ESCMID Online Lecture Library
The Karyatides at the Erechtheion Temple Devoted to the Women in the Audience At the top of the Museum the Karyatides, watching you through the years to come FOSFOMYCIN IN THE TREATMENT OF INFECTIONS
More informationExpert rules in antimicrobial susceptibility testing: State of the art
Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario
More informationAilyn T. Isais-Agdeppa, MD*, Lulu Bravo, MD*
A FIVE-YEAR RETROSPECTIVE STUDY ON THE COMMON MICROBIAL ISOLATES AND SENSITIVITY PATTERN ON BLOOD CULTURE OF PEDIATRIC CANCER PATIENTS ADMITTED AT THE PHILIPPINE GENERAL HOSPITAL FOR FEBRILE NEUTROPENIA
More informationOnline Supplement for:
Online Supplement for: INFLUENCE OF COMBINED INTRAVENOUS AND TOPICAL ANTIBIOTIC PROPHYLAXIS ON THE INCIDENCE OF INFECTIONS, ORGAN DYSFUNCTIONS, AND MORTALITY IN CRITICALLY ILL SURGICAL PATIENTS A PROSPECTIVE,
More informationAntibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)
Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336
More information5/1/2015 SEPSIS SURVIVING SEPSIS CAMPAIGN HOW TO APPROACH THE POSSIBLE SEPTIC CHILD 2015 INFECTION CAN BE CONFIRMED BY:
SURVIVING SEPSIS CAMPAIGN HOW TO APPROACH THE POSSIBLE SEPTIC CHILD 2015 Omer Nasiroglu MD Baptist Children s Hospital Pediatric Emergency Department SEPSIS IS A SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
More informationOptimizing MALDI-TOF Use. Clinical Impact Laboratory Impact
Optimizing MALDI-TOF Use Clinical Impact Laboratory Impact Christine C. Ginocchio, PhD, MT (ASCP) Clinical Professor of Medicine Hofstra North Shore-LIJ School of Medicine, NY VP, Global Microbiology Affairs,
More informationClinical Trial Data Supporting FDA Clearance of the T2Bacteria Panel Versus Blood Culture for the Diagnosis of Bacteremia
Clinical Trial Data Supporting FDA Clearance of the T2Bacteria Panel Versus Blood Culture for the Diagnosis of Bacteremia New diagnostic test overcomes time, sensitivity, and antimicrobial interference
More informationAminoglycosides John A. Bosso, Pharm.D.
AMINOGLYCOSIDES Therapeutics/PHRMP-73 Aminoglycoside Mechanism of Action Aminoglycosides bind to 30s ribosomal subunit resulting in mistranslation of mrna thus disrupting protein synthesis. They are rapidly
More informationDilemmas in Septic Shock
Dilemmas in Septic Shock William Janssen, M.D. Assistant Professor of Medicine National Jewish Health University of Colorado Denver Health Sciences Center A 62 year-old female presents to the ED with fever,
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationBacteriemia and sepsis
Bacteriemia and sepsis Case 1 An 80-year-old man is brought to the emergency room by his son, who noted that his father had become lethargic and has decreased urination over the past 4 days. The patient
More informationCeftizoxime in the treatment of infections in patients with cancer
Journal of Antimicrobial Chemotherapy (98), Suppl. C, 67-73 Ceftizoxime in the treatment of infections in patients with cancer V. Fainstein, R. Bolivar,. Elting, M. Valdivieso and G. P. Bodey Department
More informationLimiting the Attributable Mortality of. Healthcare-Associated Infection & Multidrug Resistance. in Critically Ill Patients
Sigma Theta Tau International 26 th International Nursing Research Congress San Juan, Puerto Rico, 23-27 July 2015 Limiting the Attributable Mortality of Healthcare-Associated Infection & Multidrug Resistance
More informationTopical antimicrobial agents in wound care. Professor Val Edwards-Jones Manchester Metropolitan University UK
Topical antimicrobial agents in wound care Professor Val Edwards-Jones Manchester Metropolitan University UK Antimicrobial agents Antibacterial agents Antifungal agents Antiviral agents Antiparasitic agents?others
More informationBasic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics
Basic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics This patient needs antibiotics. But which ones? Intensive care patient Ceftazidime,
More informationProfessor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence
Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence Researching field Pharmacokinetics, Pharmacodynamics of antimicrobial, antifungal and antitumoral drugs
More informationClinical Comparison of Cefotaxime with Gentamicin plus Clindamycin in the Treatment of Peritonitis and Other Soft-Tissue Infections
REVIEWS OF INFECTIOUS DISEASES. VOL. 4, SUPPLEMENT. SEPTEMBER-OCTOBER 982 982 by The University of Chicago. All rights reserved. 062-0886/82/0405-022$02.00 Clinical Comparison of with Gentamicin plus Clindamycin
More informationCAP, HCAP, HAP, VAP. 1. In 1898, William Osler described community-acquired pneumonia as:
1. In 1898, William Osler described community-acquired pneumonia as: Brad Sharpe, M.D. Professor of Clinical Medicine Department of Medicine UCSF sharpeb@medicine.ucsf.edu I have no relevant financial
More informationCONSIDERATIONS IN UTI DETECTION AND POTENTIAL IMPACT ON ANTIBIOTIC STEWARDSHIP
CONSIDERATIONS IN UTI DETECTION AND POTENTIAL IMPACT ON ANTIBIOTIC STEWARDSHIP ERIN H. GRAF, PHD, D(ABMM) Director, Infectious Disease Diagnostics Laboratory Assistant Professor, Clinical Pathology and
More informationDevelopment of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s
Beta-lactam antibiotics - Cephalosporins Development of C sporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability properties
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationβ- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication
Prevalence of Carbapenem-Hydrolyzing β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication David Alcid M.D Balaji Yegneswaran M.D. Wanpen Numsuwan Introduction Klebsiella pneumoniae
More informationOsteomyelitis and Septic Joints; Practical Considerations. Coleen K. Cunningham
Osteomyelitis and Septic Joints; Practical Considerations Coleen K. Cunningham Goals/objectives To improve understanding of the diagnosis, treatment, and follow-up of pediatric bone and joint infections
More informationUsefulness of Procalcitonin in the management of Infections in ICU. P Damas CHU Sart Tilman Liège
Usefulness of Procalcitonin in the management of Infections in ICU P Damas CHU Sart Tilman Liège Procalcitonin Peptide 116 AA Produced by parenchymal cells during «sepsis»: IL1, TNF, IL6 : stimulators
More informationReceived 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005
Journal of Antimicrobial Chemotherapy (2005) 56, 1047 1052 doi:10.1093/jac/dki362 Advance Access publication 20 October 2005 Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity,
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationMICHIGAN MEDICINE GUIDELINES FOR TREATMENT OF URINARY TRACT INFECTIONS IN ADULTS
When to Order a Urine Culture: Asymptomatic bacteriuria is often treated unnecessarily, and accounts for a substantial burden of unnecessary antimicrobial use. National guidelines recommend against testing
More informationEndocardite infectieuse
Endocardite infectieuse 1. Raccourcir le traitement: jusqu où? 2. Proposer un traitement ambulatoire: à partir de quand? Endocardite infectieuse A B 90 P = 0.014 20 P = 0.0005 % infective endocarditis
More informationprophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures
1 Glycopeptides appropriate uses serious infections due to beta-lactam- resistant gram-positive microorganisms infections due to gram-positive microorganisms in patients with serious allergy to beta-lactam
More informationBiomarkers in sepsis: Utility in critical care
Biomarkers in sepsis: Utility in critical care Fathima Paruk, PhD Charlotte Maxeke Johannesburg Academic Hospital and University of Witwatersrand Kumar A et al, Chest 2009; 136:1237-48. von Gunten et al
More informationISF criteria (International sepsis forum consensus conference of infection in the ICU) Secondary peritonitis
Appendix with supplementary material. This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Supplementary Tables Table S1. Definitions
More informationANWICU knowledge
ANWICU knowledge www.anwicu.org.uk This presenta=on is provided by ANWICU We are a collabora=ve associa=on of ICUs in the North West of England. Permission to provide this presenta=on has been granted
More informationUrinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014
Urinary Tract Infections: From Simple to Complex Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Learning Objectives Develop empiric antimicrobial treatment
More informationImportance of kinetics of procalcitonin in septic patients. János Fazakas MD, PhD Semmelweis University, Department of Transplantation and Surgery
Importance of kinetics of procalcitonin in septic patients János Fazakas MD, PhD Semmelweis University, Department of Transplantation and Surgery Host pathogen interactions the innate and the adaptive
More informationLa farmacologia in aiuto
Ferrara, 15 giugno 2018 La farmacologia in aiuto Pier Giorgio Cojutti, Federico Pea Istituto di Farmacologia Clinica Azienda Sanitaria Universitaria Integrata di Udine Therapeutic Drug Monitoring of Beta-Lactams
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationWork up of Respiratory & Wound Cultures:
Work up of Respiratory & Wound Cultures: Culture work up 2 Systematic approaches 1 Work up of Respiratory & Wound Cultures Resident flora Colonizing organisms Pathogens 2 Work up of Respiratory & Wound
More informationThe benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection
Journal of Internal Medicine 1998; 244: 379 386 JINT379 The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection L. LEIBOVICI 1, I. SHRAGA 1, M. DRUCKER 2, H. KONIGSBERGER
More informationNephrotoxic Burden and Consequences Associated with Drug Induced AKI (D-AKI)
Nephrotoxic Burden and Consequences Associated with Drug Induced AKI (D-AKI) Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP Associate Professor, University of Pittsburgh Critical Care Medication Safety Pharmacist,
More informationPediatric Septic Shock. Geoffrey M. Fleming M.D. Division of Pediatric Critical Care Vanderbilt University School of Medicine Nashville, Tennessee
Pediatric Septic Shock Geoffrey M. Fleming M.D. Division of Pediatric Critical Care Vanderbilt University School of Medicine Nashville, Tennessee Case 4 year old male with a history of gastroschesis repaired
More informationPredictive scoring model of mortality in Gram-negative bloodstream infection
ORIGINAL ARTICLE INFECTIOUS DISEASES Predictive scoring model of mortality in Gram-negative bloodstream infection M. N. Al-Hasan 1,2, B. D. Lahr 3, J. E. Eckel-Passow 3 and L. M. Baddour 2 1) Department
More informationβ-lactamase inhibitors
β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine
More informationSepsis Treatment: Early Identification Remains the Key Issue
Sepsis Treatment: Early Identification Remains the Key Issue Marin H. Kollef, MD Professor of Medicine Washington University School of Medicine Director, Medical Critical Care Director, Respiratory Care
More informationSurviving Sepsis Campaign Guidelines 2012 & Update for David E. Tannehill, DO Critical Care Medicine Mercy Hospital St.
Surviving Sepsis Campaign Guidelines 2012 & Update for 2015 David E. Tannehill, DO Critical Care Medicine Mercy Hospital St. Louis Be appropriately aggressive the longer one delays aggressive metabolic
More informationMarcos I. Restrepo, MD, MSc, FCCP
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More informationShirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate
Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate Professor of Pharmacy & Associate Member of Medicine, UBC
More informationDELIRIUM IN SEPSIS. Professor Kevin Rooney: National Clinical Lead for Sepsis Alison Hunter: Improvement Advisor, Sepsis Collaborative
DELIRIUM IN SEPSIS Professor Kevin Rooney: National Clinical Lead for Sepsis Alison Hunter: Improvement Advisor, Sepsis Collaborative What is Sepsis? Diagnostic Criteria for Sepsis: A U.K. Perspective
More informationESCMID Online Lecture Library. by author
Novel PK/PD data on the optimisation of colistin and the carbapenems Diamantis Plachouras Athens, Greece Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course, 31
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for
More informationThink Globally: Strategies to Improve the Culture of Antibiotic Prescribing
Think Globally: Strategies to Improve the Culture of Antibiotic Prescribing October 11, 2017 Paul Lewis, PharmD, BCPS (AQ-ID) Johnson City Medical Center Johnson City, TN 1 Outline Introduction to stewardship
More informationSBUH Aminoglycoside Dosing Protocol
Adult Aminoglycoside Dosing for Gram negative infections prior to available serum levels (Excludes patients with cystic fibrosis, OB GYN patients and surgical prophylaxis) Cr Cl 40 ml/min 5 7 mg/kg INT
More informationA Multicentre Study about Pattern and Organisms Isolated in Follow-up Blood Cultures
Ann Clin Microbiol Vol., No., March, 0 http://dx.doi.org/0./acm.0... ISSN -0 A Multicentre Study about Pattern and Organisms Isolated in Follow-up Blood Cultures Jeong Hwan Shin, Eui Chong Kim, Sunjoo
More informationVancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy
Vancomycin Pharmacokinetics Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy Goals Review the PK properties of vancomycin Compare and contrast methods of dosage regimen design for vancomycin
More informationSepsis and Antimcrobial Stewardship: Are they really mutually Exclusive?
Sepsis and Antimcrobial Stewardship: Are they really mutually Exclusive? DR KATE ADAMS CONSULTANT INFECTIOUS DISEASES HULL AND EAST YORKSHIRE NHS TRUST AMS Sepsis No! At least not if the sepsis programme
More informationESCMID Online Lecture Library. by author
www.eucast.org EXPERT RULES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Departamento de Microbiología II Universidad
More informationAdenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes
Adenium Biotech Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Board of Directors: - Stephan Christgau, PhD, chairman,
More informationHealthcare-associated infections acquired in intensive care units
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Healthcare-associated infections acquired in intensive care units Key facts In 2015, 11 788 (8.3%) of patients staying in an intensive care unit
More informationBlood culture 壢新醫院 病理檢驗科 陳啟清技術主任
Blood culture 壢新醫院 病理檢驗科 陳啟清技術主任 A Positive Blood Culture Clinically Important Organism Failure of host defenses to contain an infection at its primary focus Failure of the physician to effectively eradicate,
More information